Early Certainty Initiative Of The European Patent Office – Flexibility For Biotech Needed

In 2016, the European Patent Office (EPO) introduced a streamlined opposition procedure that should simplify opposition proceedings and deliver decisions faster, while giving parties more time to react to summons and prepare for oral proceedings. This new initiative, called early certainty, aimed to cut down the overall duration of granting new patents and to tackle the backlog in patent granting within the EPO, writes Michael Kahnert.

Today – UN Human Rights Council To Hear Rapporteur’s Report On Government Surveillance Online

The United Nations Human Rights Council today (6 March) is expected to hear a report on government surveillance to be presented by the UN special rapporteur on the right to privacy. The report calls for the urgent development of a comprehensive legal framework on privacy and surveillance in cyberspace.

USTR Lighthizer To NAFTA Partners: Step Up Pace Or Lose Window Of Opportunity

United States Trade Representative Robert Lighthizer warned his Mexican and Canadian counterparts today (5 March) that if they don't quickly pick up the pace of the North American Free Trade Agreement (NAFTA) renegotiations, they will face "headwinds" from elections in all three countries. And if they can't progress, the US is prepared to proceed bilaterally.

USPTO To Reveal New Design For Patents This Week

The United States Patent and Trademark Office (USPTO) will make public the new design for patents this week at the South by Southwest (SXSW) Interactive Festival in Austin, Texas. The new design will first be used on patent number 10 million, expected to issue this year. There have fewer than 12 basic design changes to the US patent since President George Washington granted the first patent in 1790, and only two in the last 100 years, USPTO said.

Tough Talk On Transatlantic Privacy, Once Again

The EU Commissioner for Justice, Consumers and Gender Equality, Věra Jourová, ahead of her US visit announced “a tough tone” on remaining gaps in the implementation of the privacy shield, the arrangement that allows to transfers of data of EU citizens to the United States. Speaking before the EU Parliament's Committee on Civil Liberties (LIBE), Jourová said while she had heard the privacy shield was not a priority of the US administration, “it will be a priority, if we make clear that we will suspend the system if it doesn't work,” adding, “My patience is coming to an end.”

A Look At The Role Of Governments, Universities, Science In Health Innovation & Access

Intellectual property rights, particularly patents, are considered by some as being a barrier in access to medicines despite being a stimulus for innovation. At a recent symposium co-organised by the World Health Organization, World Trade Organization and World Intellectual Property Organization, speakers also talked about the role of science, governments, and universities in health innovation and access, and how to address challenges such as secondary patents.

Protecting And Promoting Copyright Balance In NAFTA

The ongoing NAFTA renegotiation presents a prime opportunity to move the ball on protecting and promoting general public interest copyright exceptions. All three countries have such exceptions to varying degree. And all three are under threat from an agenda to cabin their use through international law. NAFTA negotiators can and should include the best models from prior international agreements that protect and promote the ability of countries to have general exceptions, writes Professor Sean Flynn.

WHO Joint Tropical Disease Program Issues Report On Research Fairness

The World Health Organisation's Special Programme for Research and Training in Tropical Diseases (TDR) has published the first report on research fairness under a new initiative. The report includes an analysis of how TDR manages intellectual property rights in a positive way.

Medicines Vastly Overpriced, Generics Too: Discussion At WTO-WIPO-WHO Symposium

The price of hepatitis C medicine marked a turning point in the discussion on access to medicines, with developed countries suddenly confronted to prices they could not afford. This week, a symposium jointly organised by the World Health Organization, the World Trade Organization, and the World Intellectual Property Organization explored the question of the pricing of medicines. A number of suggestions were made to alleviate the issue, such as ensuring wide use of generic medicines, encouraging competition, and alerting countries about the cost of medicine production so they negotiate better with pharmaceutical companies.